Literature DB >> 20531300

New insights into apoptosis signaling by Apo2L/TRAIL.

F Gonzalvez1, A Ashkenazi.   

Abstract

Apoptosis ligand 2 tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) belongs to a small subset of proapoptotic protein ligands in the TNF superfamily. This subset, which also includes Fas ligand and TNF-alpha, can activate the extrinsic apoptotic cell death pathway on binding to cognate death receptors at the cell surface. Over the past 10 years, Apo2L/TRAIL has emerged as a promising candidate for cancer therapy, on the basis of its unique ability to trigger apoptosis in various types of cancer cells without significant toxicity toward normal cells. Herein, we review key advances in understanding the molecular events that control apoptosis signaling by Apo2L/TRAIL, which may aid in the development of cancer therapies based on the extrinsic apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20531300     DOI: 10.1038/onc.2010.221

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  141 in total

Review 1.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

Review 2.  Fas death receptor signalling: roles of Bid and XIAP.

Authors:  T Kaufmann; A Strasser; P J Jost
Journal:  Cell Death Differ       Date:  2011-09-30       Impact factor: 15.828

3.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2).

Authors:  Nathan W Werneburg; Steve F Bronk; Maria Eugenia Guicciardi; Laurel Thomas; Jimmy D Dikeakos; Gary Thomas; Gregory J Gores
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

Review 4.  Keratins in health and cancer: more than mere epithelial cell markers.

Authors:  V Karantza
Journal:  Oncogene       Date:  2010-10-04       Impact factor: 9.867

5.  The dark side of TRAIL signaling.

Authors:  S Fulda
Journal:  Cell Death Differ       Date:  2013-07       Impact factor: 15.828

Review 6.  Imprinted and X-linked non-coding RNAs as potential regulators of human placental function.

Authors:  Sam Buckberry; Tina Bianco-Miotto; Claire T Roberts
Journal:  Epigenetics       Date:  2013-09-30       Impact factor: 4.528

7.  Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.

Authors:  Matthieu C J Bosman; Carlos R Reis; Jan J Schuringa; Edo Vellenga; Wim J Quax
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

8.  Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function.

Authors:  You-Take Oh; Guoqing Qian; Jiusheng Deng; Shi-Yong Sun
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

9.  Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.

Authors:  Heather A Huet; Joseph D Growney; Jennifer A Johnson; Jing Li; Sanela Bilic; Lance Ostrom; Mohammad Zafari; Colleen Kowal; Guizhi Yang; Axelle Royo; Michael Jensen; Bruno Dombrecht; Kris R A Meerschaert; Joost A Kolkman; Karen D Cromie; Rebecca Mosher; Hui Gao; Alwin Schuller; Randi Isaacs; William R Sellers; Seth A Ettenberg
Journal:  MAbs       Date:  2014       Impact factor: 5.857

10.  Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib.

Authors:  Makoto Edagawa; Junya Kawauchi; Manabu Hirata; Hiroto Goshima; Makoto Inoue; Tatsuro Okamoto; Akira Murakami; Yoshihiko Maehara; Shigetaka Kitajima
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.